NCI Immunotherapy Fellowship

A one-year visiting fellowship at the National Cancer Institute (NCI) beginning July 2026.
Application period: July 8–Aug. 19, 2025


Co-sponsored by the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC) and made possible in part by an educational grant from EMD Serono.

Eligibility Criteria

  • Able to relocate to Bethesda, MD for the duration of the fellowship
  • Trained in medical oncology, hematology, pediatric oncology, radiation oncology, or surgical oncology
  • Strong interest in learning about immunotherapy
  • Preference is given to those with an academic interest
  • Open to U.S. and non-U.S. trained physicians (the latter requires ECFMG certification and completion of USMLE Step 1, 2, and 3)

Benefits

  • Provides opportunities to understand how to design, write, and run clinical trials, how to treat patients, how to manage toxicities, as well as opportunities to work with multiple experimental agents
  • Work with internationally recognized experts in immunotherapy
  • Learn management of immune-related adverse events
  • Develop experience in writing and running immunotherapy clinical trials
  • Develop experience with a wide array of immunotherapy approaches
    • Cellular therapy (e.g., CAR-T or TCR transgenic approaches)
    • Combination immunotherapy approaches
    • Immune checkpoint inhibitors
    • Immunocytokines
    • Therapeutic vaccines
  • Possibilities for attending and presenting at national/international meetings
  • Attend and participate in regularly scheduled NIH immunotherapy conferences
  • Make a difference in the lives of patients with cancer at the largest hospital in the world devoted solely to research
  • Salary is based on applicable laws, regulations, and policies

NCI Fellowship PDF

For more information regarding the 2025 SITC-NCI Fellowship Application,
click here.

Questions?

If you have questions about the SITC-NCI Fellowship, please contact the SITC Education team.

Previous Recipients

Discover previous recipients of the NCI Immunotherapy Fellowship here.